http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Press+Releases/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html <ul class="bwlistdisc"> <li> <b>New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Builds on more than 3,300 cumulative placements of the established QIAsymphony platform while using the same QIAsymphony kits and consumables</b> </li> </ul><ul class="bwlistdisc"> <li> <b>Supports high-growth applications such as liquid biopsy</b> </li> </ul> <p> VENLO, Netherlands &amp; HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. </p><p> Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction http://www.streetinsider.com/Business+Wire/QIAGEN+Launches+QIAsymphony+Connect+for+Automated+Clinical+Nucleic+Acid+Extraction/26989791.html Thu, 27 Aug 2026 16:05:00 -0400 A.06822034 O.00543542 O.20026344 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Press+Releases/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html <ul class="bwlistdisc"> <li> <b>Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall</b> </li> <li> <b>To assume CEO role on September 1, 2026, succeeding Thierry Bernard</b> </li> <li> <b>QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues</b> </li> </ul> <p> VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. </p><p> Jon Pratt most http://www.streetinsider.com/Business+Wire/QIAGEN+Appoints+Jonathan+M.+Pratt+as+Chief+Executive+Officer/26965310.html Mon, 24 Aug 2026 09:47:00 -0400 A.13123098 A.24921274 A.50207256 O.00000783 O.00332782 O.00543542 O.03755842 QGEN QIA